QuatRx files for $86.2M IPO

QuatRx Pharmaceuticals of Ann Arbor, MI, has filed for an IPO designed to raise $86.2 million. QuatRx was founded in 2000 and has been developing drugs for cardiovascular, metabolic and endocrine disorders. The underwriters of the offering will be Banc of America Securities, as sole book-running manager, SG Cowen & Co., as co-lead manager, and Lazard Capital Markets and Pacific Growth Equities as co-managers.

- read this release for more information

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.